Two women discussing efruxifermin, or EFX, in front of a whiteboard

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

PUBLICATIONS SHOULD BE DELIVERED SEPARATELY USING A SPREADSHEET PROGRAM (EXCEL OR SHEETS)

Filter

May 2025 | FROM AKERO THERAPEUTICS

qFibrosis enables earlier detection of fibrosis response in Efruxifermin-treated patients with F2-F3 MASH in 96-week HARMONY study

Jörn M. Schattenberg, Dean Tai, Elaine Chng, Yukti Choudhury, Galvin Gan, Cynthia Behling, Pierre Bedossa, Doreen Chan, Jimmie Zhang, Erica Fong, Brittany de Temple, Matthew Minerva, Mark Burch, Kimberly Barrett, Reshma Shringarpure, Erik Tillman, Tim Rolph, Andrew Cheng, Kitty Yale, Mazen Noureddin EASL 2025

May 2025 | FROM AKERO THERAPEUTICS

Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, double-blind, placebo-controlled, phase 2b trial (SYMMETRY)

Mazen Noureddin, Mary E Rinella, Naga P Chalasani, Guy Neff, K Jean Lucas, Manuel E Rodriguez, Madhavi Rudraraju, Rashmee Patil, Cynthia Behling, Mark Burch, Doreen Chan, Erik J Tillman, Arian Zari BS, Brittany de Temple, Reshma Shringarpure, Meena Jain, Tim Rolph, Andrew Cheng, Kitty Yale EASL 2025

Jan 2025 | FROM AKERO THERAPEUTICS

Pleiotropic effects of FGF21 in liver, brain, and adipose tissue

Tim Rolph MASH-TAG 2025

Dec 2024 | FROM AKERO THERAPEUTICS

Improvement of liver fibrosis in efruxifermin-treated patients with MASH: correlation between conventional histopathology, AI-based digital histopathology, and non-invasive biomarkers of fibrosis

Erik J Tillman, Doreen Chan, Reshma Shringarpure, Yukti Choudhury, Elaine Chng, Dean Tai, Kitty Yale, Tim Rolph Keystone Symposia Fibrosis: Inflammation, Drivers, and Therapeutic Resolution

May 2024 | From Akero Therapeutics

FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond

Stephen A. Harrison, Tim Rolph, Maddie Knot, Julie Dubourg Journal of Hepatology

Oct 2023 | From Akero Therapeutics

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebocontrolled, phase 2b trial

Stephen A Harrison, Juan P Frias, Guy Neff, Gary A Abrams, K Jean Lucas, William Sanchez, Sudhanshu Gogia, Muhammed Y Sheikh, Cynthia Behling, Pierre Bedossa, Lan Shao, Doreen Chan, Erica Fong, Brittany de Temple, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale, for the HARMONY Study Group The Lancet Gastroenterology & Hepatology

Mar 2023 | From Akero Therapeutics

Efruxifermin, a long-acting, bivalent FGF21 analog, normalized noninvasive measures of liver injury, fibrosis, and metabolic health in patients with NASH and F2/F3 fibrosis over 24 weeks

Doreen Chan, Erik J Tillman, Reshma Shringarpure, Andrew Cheng, Stephen A Harrison, Kitty Yale, Tim Rolph Keystone Symposium: Metabolic and Molecular Mechanisms of NAFLD/NASH

Mar 2023 | From Akero Therapeutics

Efruxifermin, a bivalent Fc-FGF21 analog, demonstrated improved biophysical and pharmacological engagement with live cells compared to monovalent FGF21 analogs

Erik J Tillman, Sina Bondza, Louben Dorval, Anna Boström, Tim Rolph Keystone Symposium: Metabolic and Molecular Mechanisms of NAFLD/NASH

Close up of multichannel micropipette filling four small blue centrifuge tubes

We have developed a comprehensive clinical program to evaluate EFX as a potential treatment for MASH.

View Our Pipeline